Therapy Just As Effective As Antidepressants In Addressing Depressive Disorders: Study

Antidepressants seem to be no better at treating major depressive disorders than seeing a therapist, according to the findings of a new study.

At five years, cognitive behavioral therapy and second-generation antidepressants were about equal in efficacy and cost-effectiveness, according to University of Michigan researchers, who published their findings earlier this month in The Annals of Internal Medicine.

Researchers used data from an analysis of randomized controlled trials, as well as additional clinical and economic data from other publications. They included adults with a new diagnosis of major depressive disorder in the U.S.

Did You Know?

Ticketmaster Data Breach Impacts Millions of Customers

A massive Ticketmaster data breach exposed the names, addresses, phone numbers, credit card numbers and other personal information of more than 560 million customers, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

Most guidelines for depression recommend treatment with antidepressants or cognitive behavioral therapy. Many people opt for simply taking a pill, rather than spending the time week after week in therapy. In this study, researchers set out to determine if one was superior to the other.

According to the findings, both produced similar quality adjusted life years. At the one-year mark, therapy produced three days more of quality adjusted life years than antidepressants. At the five-year mark, therapy produced 20 more days.

Similarly, therapy cost patients more by one year, but at five years it had lower costs.

A cost analysis showed antidepressants had a 64% to 77% likelihood of having a cost effectiveness ratio of $100,000 per quality life year while therapy had a 73% to 77% likelihood at five years.

Since both are fairly equal in treatment and cost effectiveness, which therapy to use should be determined based on other factors, such as individual patient values and preferences, the researchers concluded. They indicated that increasing patient access to therapy should be a focus in the future, given the results.

Study authors found that more people newly diagnosed to depression should first try therapy, either individually or in group sessions, before deciding to take an antidepressant. Taking antidepressant drugs can always be a follow-up option if therapy doesn’t seem to be helping in the long run.

“Neither antidepressants nor cognitive behavioral therapy provides consistently superior cost-effectiveness relative to the other,” the researchers concluded. “Given many patients’ preference for psychotherapy over pharmacotherapy, increasing patient access to cognitive behavioral therapy may be warranted.”

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Ozempic MDL Court To Evaluate Need for Gastroparesis Diagnostic Testing in GLP-1 Lawsuits
Ozempic MDL Court To Evaluate Need for Gastroparesis Diagnostic Testing in GLP-1 Lawsuits (Posted yesterday)

A federal judge has agreed to divide lawsuits over gastroparesis injuries linked to drugs like Ozempic and Mounjaro into multiple phases, examining how the condition is diagnosed and whether plaintiffs' claims are preempted by federal laws.

Adult Woman Files Similac Lawsuit Over NEC Injuries Experienced as a Newborn
Adult Woman Files Similac Lawsuit Over NEC Injuries Experienced as a Newborn (Posted 2 days ago)

Lawsuit alleges that Abbott Laboratories failed to provide families and the medical community with adequate warnings about the risks associated with it’s cow’s milk-based Similac formula, which a now adult woman indicates has left her with life-long NEC injuries.

Amended Lawsuit Over BioZorb Implant Side Effects Outlines Problems Caused By Tissue Marker Design Defects
Amended Lawsuit Over BioZorb Implant Side Effects Outlines Problems Caused By Tissue Marker Design Defects (Posted 3 days ago)

Six breast cancer patients have asked a federal judge for permission to amend a complaint filed in March 2024, which describes problems linked to the device and painful side effects experienced when the tissue marker migrated out of position or shattered inside their bodies.